Clinical progression of progressive supranuclear palsy: impact of trials bias and phenotype variants. (2021)
Attributed to:
A new noradrenergic strategy to treat Impulsivity in Progressive Supranuclear Palsy
funded by
MRC
Abstract
No abstract provided
Bibliographic Information
Digital Object Identifier: http://dx.doi.org/10.1093/braincomms/fcab206
PubMed Identifier: 34541533
Publication URI: http://europepmc.org/abstract/MED/34541533
Type: Journal Article/Review
Volume: 3
Parent Publication: Brain communications
Issue: 3
ISSN: 2632-1297